Replies to post #36641 on Humanigen Inc (HGENQ)

[DonDonDonDon]

hgen on the cusp of positive data and has half the market cap of cydy a total scam .
just goes to show what the market thinks of hgen chances of any approval.
slim to none

The market thinks HGEN is the same as CYDY or RLFTF. They view all smallcap bio as greasy. They see the Sept 9th EUA decline but don't know the data so they don't understand how close lenzilumab was to getting the EUA.

The primary endpoint population of the BET-B trial had 7.5% lenz mortality and 17.3% placebo mortality in the LIVE-AIR trial. No therapeutic comes close to that efficacy. And it isn't datamining. That subgroup represents well over 50% of patients of the LIVE-AIR trial and it makes sense that earlier treatment would be more effective than later treatment since GM-CSF is upstream. GM-CSF is the master controller. GM-CSF is the cytokine that begins the cytokine storm by beckoning other cytokines. Once the cytokine storm is on full blast, it is too late.

https://www.bbc.com/news/health-56352128

[OneDay4488]

Management inability to attract attention